◆英語タイトル:Tobira Therapeutics Inc (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013247
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Tobira Therapeutics Inc (Tobira), formerly Regado Biosciences, Inc, which develops and commercializes therapies for the treatment of to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Its pipeline products include Cenicriviroc (CVC) and Evogliptin (EVO). The company’s lead product candidate, cenicriviroc, is a proprietary immunomodulator which is used to treat diseases such as HIV-1, and others. Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 inhibitor which prevents the breakdown of incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The company seeks partnership for in-licensing and combination therapy development for the fibrosis, inflammation and HIV. Tobira is headquartered in San Francisco, California, the US.
Tobira Therapeutics Inc (TBRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Tobira Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Regado Biosciences Raises US$51 Million In Series E Financing 12
Regado Biosciences Raises US$6.8 Million In Venture Financing 14
Regado Biosciences Secures US$11.6 Million In Financing 15
Merger 16
Regado Biosciences Merges with Tobira Therapeutics 16
Licensing Agreements 18
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 18
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 19
Equity Offering 20
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 20
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 21
Tobira Therapeutics Withdraws IPO 22
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 24
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 26
Regado Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$43 Million 27
Debt Offering 29
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 29
Acquisition 30
Allergan Acquires Tobira Therapeutics in Tender Offer 30
Tobira Therapeutics Inc – Key Competitors 32
Tobira Therapeutics Inc – Key Employees 33
Tobira Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Financial Announcements 35
Aug 09, 2016: Tobira Therapeutics Reports Second Quarter 2016 Financial and Business Results 35
May 09, 2016: Tobira Therapeutics Reports First Quarter 2016 Financial and Business Results 36
Mar 03, 2016: Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business ResultsC 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tobira Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Tobira Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Regado Biosciences Raises US$51 Million In Series E Financing 12
Regado Biosciences Raises US$6.8 Million In Venture Financing 14
Regado Biosciences Secures US$11.6 Million In Financing 15
Regado Biosciences Merges with Tobira Therapeutics 16
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 18
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 19
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 20
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 21
Tobira Therapeutics Withdraws IPO 22
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 24
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 26
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 27
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 29
Allergan Acquires Tobira Therapeutics in Tender Offer 30
Tobira Therapeutics Inc, Key Competitors 32
Tobira Therapeutics Inc, Key Employees 33